Identifying Changes in Food Behaviors Associated With Beginning GLP-1 Medication

NCT ID: NCT06843512

Last Updated: 2025-09-10

Basic Information

• Recruitment Status: RECRUITING
• Total Enrollment: 25 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2025-07-15
• Study Completion Date: 2026-12-31

Brief Summary

In recent years, GLP-1 medications have become a widely employed approach by physicians to address weight concerns in patients and lead to weight loss. Little is known, however, about how these medications may alter an individual's attitude towards food, food reactivity, or the specific types and amounts of foods an individual will choose. The purpose of this study is to observe the changes an individual experiences in their relationship and reaction to food and in their food selection prior to or within the first two weeks of taking GLP-1 medication to after three months on the medication. The researchers of this study believe that an understanding of such changes can inform questions seeking to ensure maintenance of appropriate nutrient balance within individuals on weight loss medications.

Conditions

Weight Loss; Food Selection

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Interventions

GLP-1 Medication Initiation

One visit before starting GLP-1 medication and one visit 3 months after. No other changes administered between visits.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Adults (18+) with overweight or obesity (BMI >25 kg/m2)
• Not currently taking an incretin-based medication at baseline
• Recently (within two weeks) prescribed a GLP-1, can be included if they have a obesity-related co-occurring condition (diabetes, hypertension, cardiovascular disease, dyslipidemia)
• Have had no prior diagnosis of cognitive or physical disability, dyslexia, or epilepsy.
• Fluent in English

Exclusion Criteria

• Adults (18+) without overweight or obesity
• <18 years of age at time of testing
• Adults not taking a GLP-1 Medication
• Adults taking a compound GLP-1
• Adults on GLP-1 medication for longer than 2 weeks at baseline
• Have had a prior diagnosis of cognitive or physical disability, dyslexia, or epilepsy.
• Not fluent in English

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Penn State University

OTHER

Sponsor Role: lead

Responsible Party

Travis Masterson

Assistant Professor and Director of the Health, Ingestive Behavior, and Technology Lab

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Travis Masterson

Role: PRINCIPAL_INVESTIGATOR

The Pennsylvania State University

Locations

Health, Ingestive Behavior, and Technology Laboratory of Pennsylvania State University

State College, Pennsylvania, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Christina M Blackmon

Role: CONTACT

cmb8633@psu.edu

425-499-8049

Facility Contacts

Christina M Blackmon

Role: primary

cmb8633@psu.edu

425-499-8049

Other Identifiers

STUDY00026642

Identifier Type: -

Identifier Source: org_study_id